207 related articles for article (PubMed ID: 36903539)
21. Binding and selectivity studies of phosphatidylinositol 3-kinase (PI3K) inhibitors.
Al Hasan M; Sabirianov M; Redwine G; Goettsch K; Yang SX; Zhong HA
J Mol Graph Model; 2023 Jun; 121():108433. PubMed ID: 36812742
[TBL] [Abstract][Full Text] [Related]
22. PI3K signaling pathway in normal B cells and indolent B-cell malignancies.
Pongas G; Cheson BD
Semin Oncol; 2016 Dec; 43(6):647-654. PubMed ID: 28061982
[TBL] [Abstract][Full Text] [Related]
23. Computational investigation of
Yousaf MA; Anwer SA; Basheera S; Sivanandan S
J Biomol Struct Dyn; 2024; 42(4):1901-1923. PubMed ID: 37154824
[TBL] [Abstract][Full Text] [Related]
24. Discovery of novel selective PI3Kγ inhibitors through combining machine learning-based virtual screening with multiple protein structures and bio-evaluation.
Zhu J; Li K; Xu L; Cai Y; Chen Y; Zhao X; Li H; Huang G; Jin J
J Adv Res; 2022 Feb; 36():1-13. PubMed ID: 35127160
[TBL] [Abstract][Full Text] [Related]
25. Pharmacophore modeling, multiple docking, and molecular dynamics studies on Wee1 kinase inhibitors.
Hu Y; Zhou L; Zhu X; Dai D; Bao Y; Qiu Y
J Biomol Struct Dyn; 2019 Jul; 37(10):2703-2715. PubMed ID: 30052133
[TBL] [Abstract][Full Text] [Related]
26. SHC014748M, a novel selective inhi-bitor of PI3Kδ, demonstrates promising preclinical antitumor activity in B cell lymphomas and chronic lymphocytic leukemia.
Fan L; Wang C; Zhao L; Wang Z; Zhang X; Liu X; Cao L; Xu W; Li J
Neoplasia; 2020 Dec; 22(12):714-724. PubMed ID: 33142237
[TBL] [Abstract][Full Text] [Related]
27. 3D QSAR, Docking, Molecular Dynamics Simulations and MM-GBSA studies of Extended Side Chain of the Antitubercular Drug (6S) 2-Nitro-6- {[4-(trifluoromethoxy) benzyl] oxy}-6,7-dihydro-5H-imidazo[2,1-b] [1,3] oxazine.
Chaudhari HK; Pahelkar A
Infect Disord Drug Targets; 2019; 19(2):145-166. PubMed ID: 30324898
[TBL] [Abstract][Full Text] [Related]
28. Development of Effective Therapeutic Molecule from Natural Sources against Coronavirus Protease.
Fadaka AO; Sibuyi NRS; Martin DR; Klein A; Madiehe A; Meyer M
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502340
[TBL] [Abstract][Full Text] [Related]
29. Establishing the Role of Iridoids as Potential Kirsten Rat Sarcoma Viral Oncogene Homolog G12C Inhibitors Using Molecular Docking; Molecular Docking Simulation; Molecular Mechanics Poisson-Boltzmann Surface Area; Frontier Molecular Orbital Theory; Molecular Electrostatic Potential; and Absorption, Distribution, Metabolism, Excretion, and Toxicity Analysis.
Alamri MA; Alawam AS; Alshahrani MM; Kawsar SMA; Prinsa ; Saha S
Molecules; 2023 Jun; 28(13):. PubMed ID: 37446713
[TBL] [Abstract][Full Text] [Related]
30. Cytosporone E analogues as BRD4 inhibitors for cancer treatment: molecular docking and molecular dynamic investigations.
Makki AA; Ibraheem W; Alzain AA
J Biomol Struct Dyn; 2023; 41(22):12643-12653. PubMed ID: 36644887
[TBL] [Abstract][Full Text] [Related]
31. Current status of phosphoinotiside-3 kinase inhibitors in blood cancers.
Shouse G; Danilova OV; Danilov AV
Curr Opin Oncol; 2022 Sep; 34(5):540-545. PubMed ID: 35855508
[TBL] [Abstract][Full Text] [Related]
32. Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium.
Smith SM; van Besien K; Karrison T; Dancey J; McLaughlin P; Younes A; Smith S; Stiff P; Lester E; Modi S; Doyle LA; Vokes EE; Pro B
J Clin Oncol; 2010 Nov; 28(31):4740-6. PubMed ID: 20837940
[TBL] [Abstract][Full Text] [Related]
33. Computational Investigation of 1, 3, 4 Oxadiazole Derivatives as Lead Inhibitors of VEGFR 2 in Comparison with EGFR: Density Functional Theory, Molecular Docking and Molecular Dynamics Simulation Studies.
Bilal MS; Ejaz SA; Zargar S; Akhtar N; Wani TA; Riaz N; Aborode AT; Siddique F; Altwaijry N; Alkahtani HM; Umar HI
Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36358960
[TBL] [Abstract][Full Text] [Related]
34. Discovery and optimization of triazine derivatives as ROCK1 inhibitors: molecular docking, molecular dynamics simulations and free energy calculations.
Shen M; Zhou S; Li Y; Pan P; Zhang L; Hou T
Mol Biosyst; 2013 Mar; 9(3):361-74. PubMed ID: 23340525
[TBL] [Abstract][Full Text] [Related]
35. Pharmacophore-guided fragment-based design of novel mammalian target of rapamycin inhibitors: extra precision docking, fingerprint-based 2D and atom-based 3D-QSAR modelling.
Kumar A; Rai S; Rathi E; Agarwal P; Kini SG
J Biomol Struct Dyn; 2021 Mar; 39(4):1155-1173. PubMed ID: 32037974
[TBL] [Abstract][Full Text] [Related]
36. Theoretical studies on the selectivity mechanisms of PI3Kδ inhibition with marketed idelalisib and its derivatives by 3D-QSAR, molecular docking, and molecular dynamics simulation.
Zhu J; Ke K; Xu L; Jin J
J Mol Model; 2019 Jul; 25(8):242. PubMed ID: 31338599
[TBL] [Abstract][Full Text] [Related]
37. Computational study reveals substituted benzimidazole derivatives' binding selectivity to PI3Kδ and PI3Kγ.
Zhang NN; Bai X; Zhao SS; Zheng XM; Tang L; Yang SG; Zhang JQ
J Mol Model; 2022 Apr; 28(5):123. PubMed ID: 35438328
[TBL] [Abstract][Full Text] [Related]
38. Turning down PI3K/AKT/mTOR signalling pathway by natural products: an in silico multi-target approach.
Abd Emoniem N; Mukhtar RM; Ghaboosh H; Elshamly EM; Mohamed MA; Elsaman T; Alzain AA
SAR QSAR Environ Res; 2023 Feb; 34(2):163-182. PubMed ID: 36853097
[TBL] [Abstract][Full Text] [Related]
39. Evidence of an association between non-Hodgkin's lymphoma and skin cancer.
Adami J; Frisch M; Yuen J; Glimelius B; Melbye M
BMJ; 1995 Jun; 310(6993):1491-5. PubMed ID: 7787593
[TBL] [Abstract][Full Text] [Related]
40. Computational Design of Phosphatidylinositol 3-Kinase Inhibitors.
Rani I; Goyal A; Sharma M
Assay Drug Dev Technol; 2022 Oct; 20(7):317-337. PubMed ID: 36269231
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]